Kiniksa preps BLA as Regeneron drug cruises to a PhIII win — shares soar
Kiniksa made a modest $5 million cash bet on Regeneron’s Arcalyst (rilonacept) back in 2017. The startup forged a pact to use the drug, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
